Verona Pharma plc(VRNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VRNA Verona Pharma plc

Not Yet Opened 03-31 16:00:00 EDT

63.49

+0.79

+1.26%

盘后63.55

+0.06+0.09%

19:24 EDT

High63.57	Low59.40	Vol1.19M
Open61.50	D1 Closing62.70	Amplitude6.65%
Mkt Cap5.40B	Tradable Cap3.91B	Total Shares84.98M
T/O74.22M	T/O Rate1.93%	Tradable Shares61.61M
P/B26.38	ROE-76.42%	EPS-2.16
52wk High70.40	52wk Low11.39	P/E-29.39
Dividend0.00	Div.Yield0.00	ROA-24.13%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"VRNA","market":"US","secType":"STK","nameCN":"Verona Pharma plc","latestPrice":63.49,"timestamp":1743451200000,"preClose":62.7,"halted":0,"volume":1191018,"hourTrading":{"tag":"盘后","latestPrice":63.55,"preClose":63.49,"latestTime":"19:24 EDT","volume":51256,"amount":3254252.81,"timestamp":1743463483450},"delay":0,"floatShares":61613461,"shares":84978880,"eps":-2.16,"marketStatus":"Not Yet Opened","change":0.79,"latestTime":"03-31 16:00:00 EDT","open":61.5,"high":63.57,"low":59.4,"amount":74216208.34358999,"amplitude":0.066507,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.16,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1743494400000},"marketStatusCode":0,"adr":1,"adrRate":8,"listingDate":1493265600000,"exchange":"NASDAQ","adjPreClose":62.7,"preHourTrading":{"tag":"盘前","latestPrice":61.03,"preClose":62.7,"latestTime":"09:28 EDT","volume":1007,"amount":61764.782038,"timestamp":1743427686066},"postHourTrading":{"tag":"盘后","latestPrice":63.55,"preClose":63.49,"latestTime":"19:24 EDT","volume":51256,"amount":3254252.81,"timestamp":1743463483450},"volumeRatio":1.339167,"impliedVol":0.7196,"impliedVolPercentile":0.58},"requestUrl":"/m/hq/s/VRNA/tweets","defaultTab":"tweets","newsList":[{"id":"2522572015","title":"Verona Pharma Re-Works Loan Packages, Boosting Borrowing Capacity, Lowering Expense","url":"https://stock-news.laohu8.com/highlight/detail?id=2522572015","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522572015?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 21:28","pubTimestamp":1743168494,"startTime":"0","endTime":"0","summary":"Verona Pharma  said Friday that it has revised its existing funding agreements by repaying its $100 million revenue interest purchase and sale agreement and increasing its debt facility with funds managed by Oaktree Capital Management and Omers Life Sciences to $450 million on improved terms.The biopharmaceutical company said it has also borrowed $125 million from an expanded tranche C and reduced the interest rate it pays by 130 basis points to 9.7%.The company said it can also cut its interest rate to 9.35% by reaching certain sales milestones and it has included a provision that allows it to secure up to $75 million through a working capital revolving credit facility with a separate group of lenders.Verona Pharma shares were fractionally higher in recent Friday premarket activity.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VRNA","BK4007"],"gpt_icon":0},{"id":"2522573249","title":"Verona Pharma Announces Amended Strategic Financing With Oaktree And OMERS","url":"https://stock-news.laohu8.com/highlight/detail?id=2522573249","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522573249?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 20:03","pubTimestamp":1743163422,"startTime":"0","endTime":"0","summary":"March 28 (Reuters) - Verona Pharma PLC ::*VERONA PHARMA ANNOUNCES AMENDED STRATEGIC FINANCING WITH OAKTREE AND OMERS*VERONA PHARMA PLC - AMENDS FINANCING AGREEMENTS, INCREASES DEBT FACILITY TO $450 MI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nRSD3q4r5F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRNA","BK4007"],"gpt_icon":0},{"id":"2522524776","title":"Press Release: Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS","url":"https://stock-news.laohu8.com/highlight/detail?id=2522524776","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522524776?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 19:00","pubTimestamp":1743159600,"startTime":"0","endTime":"0","summary":"Term loan facility increased to $450 million with more favorable terms. LONDON and RALEIGH, N.C., March 28, 2025  -- Verona Pharma plc  , a biopharmaceutical company focused on respiratory diseases, has amended its existing strategic financing agreements by repaying the revenue interest purchase and sale agreement  and increasing the debt facility to $450 million on improved terms with funds managed by Oaktree Capital Management, L.P.  and OMERS Life Sciences  announced in May 2024.\"We have been very impressed by the US launch of Ohtuvayre as a novel maintenance treatment for COPD,\" commented Aman Kumar, Co-Portfolio Manager for Oaktree's Life Sciences Lending platform. \"We are delighted to continue our partnership with the Company and look forward to supporting them as they expand access to this important therapy for COPD patients globally.\"","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4099","TM","BK4604","OACB.U","BK4585","BK4555","BK4588","VRNA","BK4007","03160"],"gpt_icon":0},{"id":"2522355096","title":"Jim Cramer Advises Caution on Verona Pharma (VRNA): “Risky – Sell Half and Let the Rest Ride”","url":"https://stock-news.laohu8.com/highlight/detail?id=2522355096","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522355096?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 03:48","pubTimestamp":1743018513,"startTime":"0","endTime":"0","summary":"We recently published a list of Jim Cramer Focused On These 9 Stocks Recently. In this article, we are going to take a look at where Verona Pharma plc  stands against other stocks that Jim Cramer discussed recently.Jim Cramer, host of Mad Money, expressed his frustration on March 19 about how investors often get caught up in discussions revolving around the Federal Reserve, interest rates, and the President’s trade policies, overlooking other important factors.“Every now and then, we want to make money in the worst way, and when I say the worst way, I mean the dumbest way. We wind up talking endlessly about the Fed and interest rates or the President’s trade policy, whether it’s punitive tariffs, reciprocal tariffs. Oh man, come on.”READ ALSO:Jim Cramer Talked About 7 Stocks & Stagflation FearsandJim Cramer Recently Talked About These 12 Companies. Why are we interested in the stocks that hedge funds pile into?","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jim-cramer-advises-caution-verona-194833698.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["US3Y.BOND",".IXIC","US12M.BOND","US10Y.BOND","QLD","MNQmain","TQQQ","PSQ","US6M.BOND","BK4007","US2Y.BOND","TSYW.SI","US30Y.BOND","NVIW.SI","NQmain","USAW.SI","USJW.SI","SQQQ","VRNA","QID","US7Y.BOND","US5Y.BOND"],"gpt_icon":1},{"id":"2520757405","title":"European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2520757405","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520757405?lang=en_us&edition=full_marsco","pubTime":"2025-03-17 23:00","pubTimestamp":1742223615,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts kicked off the week higher late Monday morning, rising 1.12% to 1,433.84 on the S&P Europe Select ADR Index.From continental Europe, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BCYC","NVO","BK4588","BK4162","LU0889565916.HKD","LU0648005311.SGD","BK4142","CUK","CRTO","LU0109394709.USD","LU0154236417.USD","BK4077","BK4009","BK4007","IE00BZ1G4Q59.USD","AMRN","LU1093756325.SGD","BK4141","LU1093756168.USD","BK4532","IE00BFMHRM44.USD","BK4107","BK4117","SQNS","LU0084288595.USD","AKTX","ASND","BK4599","EDAP","DAVA.AU","CLLS","VRNA","BK4082","PUK","BK4139","DAVA","TRIB","LU0320765992.SGD","DBVT","BK7104","TRVG","IE00BKVL7J92.USD","NVO.AU","BK4134","BK4585","AFG"],"gpt_icon":1},{"id":"2518027902","title":"European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2518027902","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518027902?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 23:20","pubTimestamp":1741620049,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were falling late Monday morning, dropping 2.31% on the S&P Europe Select ADR Index to 1,411.83.From continental Europe, the gainers were led by biopharmaceutical company DBV Technologies  and petroleum refiner Equinor , which rose 6.4% and 5.1%, respectively. They were followed by medical device maker EDAP TMS  and consumer goods giant Unilever , which were up 4.8% and 3.1%, respectively.The decliners from continental Europe were led by pharmaceutical company Novo Nordisk  and financial services company Banco Santander , which fell 10% and 5.7%, respectively. They were followed by biotech firm Evaxion Biotech  and internet browser company Opera , which were down 5.3% each.From the UK and Ireland, the gainers were led by biopharmaceutical company Biodexa Pharmaceuticals  and utilities company National Grid , which advanced 11% and 2.8%, respectively. They were followed by biopharmaceutical company TC Biopharm  and oil a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TCBP","BK4142","BCS","BK4082","LU0124676726.USD","BDRX","BK4117","LU0072461881.USD","LU0154236417.USD","BK4007","LU0320765646.SGD","IE00BKVL7J92.USD","NGG","NVO.AU","BK7142","UL","LU1162221912.USD","UN","CUK","BK4532","IE00BZ1G4Q59.USD","LU1093756168.USD","BK7104","OPRA","SAN","BK4592","EQNR","BK4521","LU1093756325.SGD","EDAP","BK4208","LU0689626769.HKD","BK4585","BK4588","BK4107","ULVR.UK","BP","VRNA","BK4201","DBVT","BK4207","LU0162691827.USD","NVO","BK4183","BK4599","AKTX","BK4023","EVAX","SAN.AU","AFG"],"gpt_icon":1},{"id":"2517316249","title":"European Equities Traded in the US as American Depositary Receipts Track Lower in Thursday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2517316249","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517316249?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 00:12","pubTimestamp":1741277533,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were tracking lower late Thursday morning, declining 0.61% to 1,444.24 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by Sequans Communications  and financial services company ING Groep , which rose 6.8% and 4.2% respectively. They were followed by financial services company Banco Santander  and biopharmaceutical company Genfit , which were up 2.2% each.The decliners from continental Europe were led by furniture maker Natuzzi  and pharmaceutical company Novo Nordisk , which fell 3.7% and 2.1% respectively. They were followed by biotech firm BioNTech  and biopharmaceutical company Cellectis , which lost 1.9% and 1.3% respectively.From the UK and Ireland, the gainers were led by biopharmaceutical companies TC Biopharm  and Akari Therapeutics , which advanced 16.7% and 8.8% respectively. They were followed by communications company WPP  and biopharmaceutical company Verona Pharma , which i","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BKVL7J92.USD","WPP.AU","AKTX","BK4535","LU1093756325.SGD","BK4588","ADAP","PSO","BK4548","BK7104","TCBP","BK4551","NVO.AU","BK4207","CUK","BK4111","BK7142","GNFT","ING","BK4142","BK4095","BK4107","WPP","IE00BZ1G4Q59.USD","BK4141","LU1093756168.USD","BK4117","ING.AU","BK7141","NVO","SAN","BK4007","BK4521","SAN.AU","BK4568","NTZ","BK4585","BK4204","BNTX","VRNA","AFG","IHG","BK4009","BK4599","CLLS","BK4139","BK7505","LU0154236417.USD","SQNS","BK4532"],"gpt_icon":1},{"id":"2517914367","title":"Verona Pharma plc (VRNA): A Bull Case Theory","url":"https://stock-news.laohu8.com/highlight/detail?id=2517914367","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517914367?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 21:20","pubTimestamp":1741180823,"startTime":"0","endTime":"0","summary":"We came across abullish thesison Verona Pharma plc  on Value Investing Subreddit Page by loud_keyb. In this article, we will summarize the bulls’ thesis on VRNA. Verona Pharma plc 's share was trading at $67.50 as of March 4th. VRNA’s forward P/E was 434.78 according to Yahoo Finance.Verona Pharma  has reported strong Q4 earnings, reinforcing the bullish case for its long-term growth. CEO Mark Hahn indicated that sales could approach $300 million in 2025, though the company refrained from issuing formal guidance. However, management did not contest the consensus estimate of $270 million and hinted at exceeding it. The company’s lead product, Ohtuvayre, is emerging as a market mainstay, with growing adoption and refills expected to drive recurring revenue, mirroring the success of Trelegy, where 90% of sales come from refills. Verona estimates that capturing just 5-10% of the U.S. market could generate $5.5B-$11B in annual sales, with each 1% share equating to $1.1B in revenue. The comp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/verona-pharma-plc-vrna-bull-132023995.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VRNA","BK4007"],"gpt_icon":0},{"id":"2517399249","title":"BTIG Sticks to Its Buy Rating for Verona Pharma (VRNA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517399249","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517399249?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 18:29","pubTimestamp":1741170560,"startTime":"0","endTime":"0","summary":"In a report released today, Thomas Shrader from BTIG maintained a Buy rating on Verona Pharma (VRNA – Research Report), with a price target of $83....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/btig-sticks-to-its-buy-rating-for-verona-pharma-vrna?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/btig-sticks-to-its-buy-rating-for-verona-pharma-vrna?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VRNA"],"gpt_icon":0},{"id":"2516465387","title":"European Equities Traded in the US as American Depositary Receipts Surge Higher in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2516465387","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516465387?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 00:08","pubTimestamp":1741018087,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts kicked off the week on strong note late Monday morning, surging 1.83% higher to 1,442.61 on the S&P Europe Select ADR Index.From cont","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BMPRXR70.SGD","OPRA","VRNA","BK4077","BK7505","BK4207","NCNA","BK4547","BK7095","BCYC","BK4141","BK4585","BK7511","ADAP","BK4007","AKTX","ING.AU","BK4139","BDRX","IE00BMPRXN33.USD","ING","BHP","TRVG","GNFT","BK4107","TCBP","SQNS","BK4588","BK7507","BK4020","AFG","BK4168","NOK","BK4117","BK7141","DBVT","BK4023","EVAX","BHP.AU"],"gpt_icon":0},{"id":"2516631174","title":"Beat the Market the Zacks Way: Verona, Visa, Starbucks in Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2516631174","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516631174?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 21:08","pubTimestamp":1741007280,"startTime":"0","endTime":"0","summary":"Last Friday, the three most widely followed benchmark indexes closed a mixed week. The Nasdaq Composite and the S&P 500 declined 3.5% and 1%, respectively, while the Dow Jones Industrial Average advanced about 1%.Throughout the week, the Trump administration’s tariff policies continued to influence trading in the markets. President Trump’s tariff announcements on Canada and Mexico varied between being imposed next week and being delayed till April. The probable tariff imposition on the European Union also stoked inflation fears in investors. Consumer confidence came in pretty low.However, probably the biggest event of the week was the showdown between President Trump and President Zelensky at the Oval Office. While the markets recovered after a shaky session, all eyes will be keenly on the developing situation of the U.S-Ukraine deal about ending the war with Russia.Regardless of market conditions, we, here at Zacks, provide investors with unbiased guidance on how to beat the market.As","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beat-market-zacks-way-verona-130800667.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IVV","LU0211331839.USD","LU0823417737.USD","LU0256863902.USD","USAC","SBUX","LU1061106388.HKD","FI","LU2271345857.HKD","LU2404859741.USD","LU1267930730.SGD","VOO","LU0566484027.USD","MMM","LU2023250843.SGD","LU0957808578.USD","NOBL","SPY","LU2242646821.SGD","FDN","ECDP","CYGIY","BK4547","AMGN","CHKP","LU0957791311.USD","LU2108987350.USD","OEF",".SPX","SG9999018857.SGD","VRNA","SDS","LU1559883803.SGD","SPXU","BK4581","V","IE00B19Z8W00.USD","UPRO","LU0511384066.AUD","LU0444971666.USD","LRN","LU0477156953.USD","OEX","LU2023251221.USD","LU1236620750.USD","SSO","ESmain","LU2517655374.HKD","SH"],"gpt_icon":1},{"id":"2516512565","title":"Earnings Beat: Verona Pharma plc (NASDAQ:VRNA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts","url":"https://stock-news.laohu8.com/highlight/detail?id=2516512565","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516512565?lang=en_us&edition=full_marsco","pubTime":"2025-03-02 20:24","pubTimestamp":1740918267,"startTime":"0","endTime":"0","summary":"Investors in Verona Pharma plc  had a good week, as its shares rose 2.5% to close at US$69.63 following the release of its yearly results. Revenues of US$42m beat expectations by a respectable 8.9%, although statutory losses per share increased. Verona Pharma lost US$2.16, which was 91% more than what the analysts had included in their models. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Verona Pharma after the latest results.NasdaqGM:VRNA Earnings and Revenue Growth March 2nd 2025. The most important thing to take away is that there's been a clear step-change in belief around the business' prospects, with the analysts now expecting Verona Pharma to become profitable next year. Happily, they","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/earnings-beat-verona-pharma-plc-122427021.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NDAQ","VRNA",".IXIC"],"gpt_icon":0},{"id":"2516589163","title":"Verona Pharma price target raised to $76 from $57 at Truist","url":"https://stock-news.laohu8.com/highlight/detail?id=2516589163","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516589163?lang=en_us&edition=full_marsco","pubTime":"2025-03-01 09:05","pubTimestamp":1740791118,"startTime":"0","endTime":"0","summary":"Truist analyst Joon Lee raised the firm’s price target on Verona Pharma (VRNA) to $76 from $57 and keeps a Buy rating on the shares after its Q4 ea...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/verona-pharma-price-target-raised-to-76-from-57-at-truist?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/verona-pharma-price-target-raised-to-76-from-57-at-truist?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VRNA","BK4007"],"gpt_icon":0},{"id":"2516377820","title":"Verona Pharma Is Maintained at Overweight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2516377820","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516377820?lang=en_us&edition=full_marsco","pubTime":"2025-03-01 01:40","pubTimestamp":1740764400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VRNA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 28, 2025 12:40 ET (17:40 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRNA"],"gpt_icon":0},{"id":"2514326554","title":"Verona Pharma Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2514326554","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514326554?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 20:34","pubTimestamp":1740746040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VRNA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 28, 2025 07:34 ET (12:34 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRNA"],"gpt_icon":0},{"id":"2514325196","title":"Truist Financial Reaffirms Their Buy Rating on Verona Pharma (VRNA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514325196","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514325196?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 20:27","pubTimestamp":1740745679,"startTime":"0","endTime":"0","summary":"Truist Financial analyst Joon Lee maintained a Buy rating on Verona Pharma (VRNA – Research Report) today and set a price target of $76.00. The com...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/truist-financial-reaffirms-their-buy-rating-on-verona-pharma-vrna?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/truist-financial-reaffirms-their-buy-rating-on-verona-pharma-vrna?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VRNA"],"gpt_icon":0},{"id":"2514340350","title":"Verona Pharma price target raised to $75 from $60 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2514340350","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514340350?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 19:21","pubTimestamp":1740741679,"startTime":"0","endTime":"0","summary":"H.C. Wainwright raised the firm’s price target on Verona Pharma (VRNA) to $75 from $60 and keeps a Buy rating on the shares following the Q4 report...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/verona-pharma-price-target-raised-to-75-from-60-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/verona-pharma-price-target-raised-to-75-from-60-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","VRNA"],"gpt_icon":0},{"id":"2514318312","title":"Verona Pharma Plc : Btig Raises Target Price to $83 From $77","url":"https://stock-news.laohu8.com/highlight/detail?id=2514318312","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514318312?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 16:29","pubTimestamp":1740731393,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PJ0G6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","VRNA"],"gpt_icon":0},{"id":"2514373316","title":"Verona Pharma PLC (VRNA) Q4 2024 Earnings Call Highlights: Strong Launch of Ohtuvayre Amid ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2514373316","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514373316?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 15:18","pubTimestamp":1740727102,"startTime":"0","endTime":"0","summary":"Selling, General and Administrative Expenses : $45.1 million. GuruFocus has detected 7 Warning Signs with VRNA.For the complete transcript of the earnings call, please refer to the full earnings call transcript.The company reported strong initial momentum for Ohtuvayre with more prescriptions dispensed in the first two months of Q1 2025 than in Q4 2024.Over 4,600 unique healthcare providers  have prescribed Ohtuvayre, with 55% of Tier 1 HCPs prescribing it, indicating strong market penetration.The company maintains a strong balance sheet with $400 million in cash and equivalents, providing financial stability for future growth initiatives.Verona Pharma PLC  reported a net loss of $33.8 million for Q4 2024, reflecting increased expenses related to the launch of Ohtuvayre.Research and development costs increased significantly to $44.6 million for 2024, driven by clinical trial and development expenses.Selling, general, and administrative expenses rose to $149.8 million for 2024, primaril","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/verona-pharma-plc-vrna-q4-071822299.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VRNA"],"gpt_icon":0},{"id":"2514338025","title":"Truist Securities Adjusts Verona Pharma Price Target to $76 From $57, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2514338025","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514338025?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 01:02","pubTimestamp":1740675751,"startTime":"0","endTime":"0","summary":"Verona Pharma (VRNA) has an average rating of buy and mean price target of $71.67, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VRNA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.veronapharma.com","stockEarnings":[{"period":"1week","weight":-0.0493},{"period":"1month","weight":-0.0882},{"period":"3month","weight":0.3671},{"period":"6month","weight":1.2114},{"period":"1year","weight":2.9459},{"period":"ytd","weight":0.3671}],"compareEarnings":[{"period":"1week","weight":-0.0256},{"period":"1month","weight":-0.0586},{"period":"3month","weight":-0.0455},{"period":"6month","weight":-0.0166},{"period":"1year","weight":0.0694},{"period":"ytd","weight":-0.0455}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":-0.042371},{"month":2,"riseRate":0.5,"avgChangeRate":0.048229},{"month":3,"riseRate":0.25,"avgChangeRate":-0.023426},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.063776},{"month":5,"riseRate":0.5,"avgChangeRate":-0.026344},{"month":6,"riseRate":0.25,"avgChangeRate":-0.037719},{"month":7,"riseRate":0.625,"avgChangeRate":0.1404},{"month":8,"riseRate":0.5,"avgChangeRate":0.11834},{"month":9,"riseRate":0.375,"avgChangeRate":0.007343},{"month":10,"riseRate":0.25,"avgChangeRate":-0.009258},{"month":11,"riseRate":0.375,"avgChangeRate":0.006476},{"month":12,"riseRate":0.75,"avgChangeRate":0.295436}],"exchange":"NASDAQ","name":"Verona Pharma plc","nameEN":"Verona Pharma plc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Verona Pharma plc(VRNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Verona Pharma plc(VRNA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Verona Pharma plc,VRNA,Verona Pharma plc股票,Verona Pharma plc股票老虎,Verona Pharma plc股票老虎国际,Verona Pharma plc行情,Verona Pharma plc股票行情,Verona Pharma plc股价,Verona Pharma plc股市,Verona Pharma plc股票价格,Verona Pharma plc股票交易,Verona Pharma plc股票购买,Verona Pharma plc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Verona Pharma plc(VRNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Verona Pharma plc(VRNA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction